- In recent weeks, Guardant Health and Helio Genomics each announced agreements with Quest Diagnostics to distribute their blood-based colorectal and liver cancer screening tests through Quest’s nationwide network, while the Quest board also appointed experienced healthcare executive Timothy Wentworth as a new director.
- Together, these moves deepen Quest’s role as an access point for innovative cancer detection while adding boardroom expertise in scaling complex healthcare platforms and payer-facing services.
- Next, we’ll examine how expanding access to cutting-edge blood-based cancer screening through Quest’s vast network may influence its investment narrative.
The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Quest Diagnostics Investment Narrative Recap
To own Quest Diagnostics, you need to believe it can keep growing test volumes and mix in higher value preventive and oncology testing while managing reimbursement pressure and cost inflation. The new cancer screening partnerships and Timothy Wentworth’s appointment look additive to that story but do not materially change the main near term catalyst, which is execution on higher margin advanced testing, or the biggest risk, which remains potential cuts to government reimbursement.
The integration of Guardant Health’s FDA approved Shield blood test for colorectal cancer into Quest’s nationwide network is particularly relevant here, as it directly ties Quest’s core infrastructure to a fast evolving area of preventive oncology. How effectively Quest can turn this kind of innovation access into sustained volume and revenue, while offsetting persistent pricing and policy headwinds, will be central to how the near term catalyst plays out.
Yet investors should also be aware that if reimbursement pressures under PAMA accelerate faster than Quest can offset them with internal efficiencies and higher value testing, ...
Read the full narrative on Quest Diagnostics (it's free!)
Quest Diagnostics' narrative projects $11.9 billion revenue and $1.3 billion earnings by 2028. This requires 4.1% yearly revenue growth and roughly a $0.4 billion earnings increase from $945.0 million today.
Uncover how Quest Diagnostics' forecasts yield a $218.50 fair value, a 12% upside to its current price.
Exploring Other Perspectives
Three members of the Simply Wall St Community see Quest’s fair value between US$157.30 and US$303.41, underscoring how far opinions can spread. Against that wide range, potential PAMA related reimbursement cuts could weigh on margins and test the assumptions behind more optimistic projections, so it is worth comparing several of these viewpoints before deciding how you see the company’s trajectory.
Explore 3 other fair value estimates on Quest Diagnostics - why the stock might be worth 19% less than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.
Want Some Alternatives?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com